The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers
Open accessAbstract
BACKGROUND: Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome. METHODS: The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 microg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies. RESULTS: The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (+/- standard error of the mean) for all 27 antigens was 3.67 +/- 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes. CONCLUSIONS: On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current Knowledge of Type-Specific M Antigens of Group A Streptococci
Lancefield, R. C. (1962) · The Journal of Immunology · doi:10.4049/jimmunol.89.3.307 · Cited by 780
Invasive Group A Streptococcal Infections in Ontario, Canada
Davies, H. D., McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A. E., & Low, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350803 · Cited by 736
Resurgence of Acute Rheumatic Fever in the Intermountain Area of the United States
Veasy, L. G., Wiedmeier, S. E., Orsmond, G. S., Ruttenberg, H. D., Boucek, M. M., Roth, S. J., Tait, V. F., Thompson, J. A., Daly, J. A., Kaplan, E. L., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702193160801 · Cited by 681
Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci
Beall, B., Facklam, R., & Thompson, T. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.4.953-958.1996 · Cited by 601
Taranta, A., & Markowitz, M. (1972) · Cited by 593
Active Bacterial Core Surveillance of the Emerging Infections Program Network
Schuchat, A., Hilger, T., Zell, E., Farley, M. M., Reingold, A., Harrison, L., Lefkowitz, L., Danila, R., Stefonek, K., Barrett, N., et al. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0701.010114 · Cited by 592
THE ANTIGENIC COMPLEX OF STREPTOCOCCUS HÆMOLYTICUS
Lancefield, R. C. (1928) · Journal of Experimental Medicine · doi:10.1084/jem.47.1.91 · Cited by 371
Hollingshead, S. K., Fischetti, V. A., & Scott, J. R. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35993-8 · Cited by 356
Lancefield, R. C., & Everly, W. T. T. A. O. W. N. (1957) · The Journal of Experimental Medicine · doi:10.1084/jem.106.4.525 · Cited by 282
Immunogenicity of a 26-Valent Group A Streptococcal Vaccine
Hu, M. C., Walls, M. A., Stroop, S. D., Reddish, M. A., Beall, B., & Dale, J. B. (2002) · Infection and Immunity · doi:10.1128/iai.70.4.2171-2177.2002 · Cited by 241
Self-citationEpitopes of streptococcal M proteins shared with cardiac myosin.
Dale, J. B., & Beachey, E. H. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.2.583 · Cited by 226
Self-citationStollerman, G. H. (1997) · The Lancet · doi:10.1016/s0140-6736(96)06364-7 · Cited by 204
Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain.
Bronze, M. S., & Dale, J. B. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2820 · Cited by 197
Self-citationType-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein
Beachey, E. H., Seyer, J. M., Dale, J. B., Simpson, W. A., & Kang, A. H. (1981) · Nature · doi:10.1038/292457a0 · Cited by 179
Self-citationKotloff, K. L., Corretti, M., Palmer, K., Campbell, J. D., Reddish, M. A., Hu, M. C., Wasserman, S. S., & Dale, J. B. (2004) · JAMA · doi:10.1001/jama.292.6.709 · Cited by 173
Self-citationStreptococcal diseases and the immune response
Read, S., & Zabriskie, J. B. (1980) · Academic Press eBooks · Cited by 170
Multiple, heart-cross-reactive epitopes of streptococcal M proteins.
Dale, J. B., & Beachey, E. H. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.1.113 · Cited by 164
Self-citationGroup A Streptococci, Mycoplasmas, and Viruses Associated With Acute Pharyngitis
Glezen, W. P. (1967) · JAMA · doi:10.1001/jama.1967.03130190061007 · Cited by 153
Miller, L., Gray, L., Beachey, E. H., et al. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60617-9 · Cited by 143
Dale, J. B. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00150-9 · Cited by 110
Self-citationMouw, A. R., Beachey, E. H., & Burdett, V. (1988) · Journal of Bacteriology · doi:10.1128/jb.170.2.676-684.1988 · Cited by 101
Manjula, B. N., Acharya, A. S., Mische, S. M., et al. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43150-4 · Cited by 100
Recombinant, octavalent group A streptococcal M protein vaccine
Dale, J. B., Simmons, M., Chiang, E. C., & Chiang, E. Y. (1996) · Vaccine · doi:10.1016/0264-410x(96)00050-3 · Cited by 84
Self-citationThe Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever
Bronze, M. S., & Dale, J. B. (1996) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)41630-1 · Cited by 78
Self-citationEpitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium
Baird, R., Bronze, M. S., Kraus, W., Hill, H. R., Veasey, L. G., & Dale, J. B. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3132 · Cited by 74
Self-citationRecombinant tetravalent group A streptococcal M protein vaccine.
Dale, J. B., Chiang, E. Y., & Lederer, J. W. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.2188 · Cited by 71
Self-citationTyrrell, G. J., Lovgren, M., Forwick, B. A., Hoe, N. P., Musser, J. M., & Talbot, J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.12.4466-4471.2002 · Cited by 69
New protective antigen of group A streptococci
Dale, J. B., Chiang, E. Y., Liu, S., Courtney, H. S., & Hasty, D. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5118 · Cited by 64
Self-citation
Cited by
Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
Walker, M. J., Barnett, T. C., McArthur, J. D., Cole, J. N., Gillen, C. M., Henningham, A., Sriprakash, K. S., Sanderson-Smith, M. L., & Nizet, V. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-13 · Cited by 908
Marijon, E., Mirabel, M., Celermajer, D. S., & Jouven, X. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61171-9 · Cited by 856
Steer, A. C., Law, I., Matatolu, L., Beall, B. W., & Carapetis, J. R. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70178-1 · Cited by 537
The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease
Seckeler, M. D., & Hoke, T. (2011) · Clinical Epidemiology · doi:10.2147/clep.s12977 · Cited by 500
The role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Metadata
- Authors
- McNeil, S. A., Halperin, S. A., Langley, J. M., Smith, B., Warren, A., Sharratt, G. P., Baxendale, D. M., Reddish, M. A., Hu, M. C., Stroop, S. D., Linden, J., Fries, L. F., Vink, P. E., & Dale, J. B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-15
- Volume
- 41
- Issue
- 8
- Pages
- 1114-1122
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2134857208
- Cited by
- 305
- References
- 28
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.